Patents by Inventor Roselyn J. Eisenberg
Roselyn J. Eisenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9089537Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.Type: GrantFiled: February 25, 2011Date of Patent: July 28, 2015Assignees: The Trustees of the University of Pennslyvania, Juvaris Biotherapeutics, Inc.Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
-
Publication number: 20130171234Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.Type: ApplicationFiled: February 25, 2011Publication date: July 4, 2013Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
-
Patent number: 7560116Abstract: The invention is directed to a poxvirus vaccine comprising a soluble truncated poxvirus envelope protein. The invention is also directed to a vaccine comprising a nucleic acid encoding such proteins. Also included is an antibody which specifically binds to the proteins and nucleic acid encoding the same, as well as methods of preventing and treating a poxvirus infection using the afore-mentioned vaccine, antibody, protein, and nucleic acid encoding them.Type: GrantFiled: December 13, 2004Date of Patent: July 14, 2009Assignee: The Trustees of the University of PennsylvaniaInventors: Gary H. Cohen, Roselyn J. Eisenberg, John Charles Whitbeck, Lydia Aldaz-Carroll, Bernard Moss, Shlomo Lustig, Christiana Fogg
-
Publication number: 20040259773Abstract: The invention includes antiherpesviral peptides and methods of generating the same.Type: ApplicationFiled: March 1, 2004Publication date: December 23, 2004Applicant: The Trustees of the University of PennsylvaniaInventors: John D. Lambris, Maria Rosa Sarrias, Gary H. Cohen, Roselyn J. Eisenberg, Patricia G. Spear, Rebecca I. Montgomery
-
Patent number: 6699481Abstract: The invention includes antiherpesviral peptides and method of generating the same.Type: GrantFiled: February 16, 2001Date of Patent: March 2, 2004Assignees: The Trustees of the University of Pennsylvania, Northwestern UniversityInventors: John D. Lambris, Maria Rosa Sarrias, Gary H. Cohen, Roselyn J. Eisenberg, Patricia G. Spear, Rebecca I. Montgomery
-
Patent number: 6641818Abstract: A cellular herpesvirus entry protein, or a mutant, a homolog, a derivative, a variant or a biologically active fragment thereof, suspended in a pharmaceutically active carrier in an amount effective to inhibit entry of an alphaherpesvirus into a cell, wherein the cellular herpesvirus entry protein is a member of the immunoglobulin superfamily, is provided and method of use thereofType: GrantFiled: November 28, 2000Date of Patent: November 4, 2003Assignee: Northwestern UniversityInventors: Patricia G. Spear, Morgyn S. Warner, Robert J. Geraghty, Wanda M. Martinez, Rebecca I. Montgomery, Gary H. Cohen, Roselyn J. Eisenberg, Charles J. Whitbeck, Claude Krummenacher
-
Publication number: 20030152583Abstract: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.Type: ApplicationFiled: February 20, 2003Publication date: August 14, 2003Applicant: The Trustees of the University of PennsylvaniaInventors: Gary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
-
Patent number: 6541459Abstract: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.Type: GrantFiled: September 8, 2000Date of Patent: April 1, 2003Assignee: The Trustees of the University of PennsylvaniaInventors: Gary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
-
Publication number: 20020119165Abstract: The invention includes antiherpesviral peptides and method of generating the same.Type: ApplicationFiled: February 16, 2001Publication date: August 29, 2002Inventors: John D. Lambris, Maria Rosa Sarrias, Gary H. Cohen, Roselyn J. Eisenberg, Patricia G. Spear, Rebecca I. Montgomery
-
Patent number: 6156319Abstract: The invention is directed to a herpes simplex virus vaccine comprising a herpes simplex virus glycoprotein H-glycoprotein L complex. The invention is also directed to a vaccine comprising a DNA encoding a herpes simplex virus glycoprotein H-glycoprotein L complex. Also included is an antibody which specifically binds to a herpes simplex virus glycoprotein H-glycoprotein L complex and DNA encoding the same.Type: GrantFiled: July 31, 1997Date of Patent: December 5, 2000Assignee: The Trustees of the University of PennsylvaniaInventors: Gary H. Cohen, Roselyn J. Eisenberg, Tao Peng, Gary Dubin
-
Patent number: 5654174Abstract: The present invention provides variant HSV-1 glycoprotein D and HSV-2 glycoprotein D molecules capable of preventing infection of cells by herpes simplex virus types 1 and/or 2. Also provided are novel purified and isolated polynucleotides encoding the variant gD molecules. HSV gD-1 and gD-2 region IV variants or fragments thereof are specifically contemplated by the invention. The presently preferred variant molecule gD-1(.DELTA.290-299t) is the product of recombinant expression in Sf9 cells of a fusion protein including the signal peptide of honeybee melittin and Patton strain HSV-1 gD wherein (1) the Patton strain amino acid residues 290 through 299 of the mature gD-1 protein have been replaced with the amino acid residues arginine, lysine, isoleucine and phenylalanine, and (2) Patton strain amino acid residues 308 through 369 have been replaced with five histidine residues.Type: GrantFiled: July 7, 1995Date of Patent: August 5, 1997Assignee: Competitive Technologies, Inc.Inventors: Gary H. Cohen, Roselyn J. Eisenberg, Anthony Nicola
-
Patent number: 5149660Abstract: Disclosed are diagnostic reagents for use in detection of Herpes Simplex Virus Type 1 antibodies or Herpes Simplex Virus Type 2 antibodies comprising novel Herpes Simplex Virus envelope glycoproteins gD-1 and gD-2, immunologically active fragments thereof, immunologically synthetic replicas, thereof, and specific polypeptides comprising specific amino acid sequences.Type: GrantFiled: June 10, 1991Date of Patent: September 22, 1992Assignee: University Patents, Inc.Inventors: Gary H. Cohen, Roselyn J. Eisenberg
-
Patent number: 4762708Abstract: Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunoadsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid sequences which are: (1) substantially common to both gD-1 and gD-2; cumulatively hydrophilic in nature; and (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification.Type: GrantFiled: February 4, 1983Date of Patent: August 9, 1988Assignee: University Patents, Inc.Inventors: Gary H. Cohen, Roselyn J. Eisenberg
-
Patent number: 4745182Abstract: Disclosed are antibody substances displaying unique, multi-specific immunoreactivities with respect to glycoprotein D of Herpes Simplex Virus types 1 and 2 (HSV gD-1 and gD-2) and structurally related compounds. Illustratively, an IgG Type 2 monoclonal antibody material produced by mouse-mouse hybridoma cell line A.T.C.C. No. HB8606 is capable of in vitro neutralization of HSV-1 and HSV-2 infectivity and of specific immunological reactivity and reversible immunobinding with natrually-occuring and recombinant gD-1 and gD-2 in both native and denatured conformations as well as with proteinaceous materials (produced, e.g., by proteolytic digestion of naturally-occurring materials, by recombinant methods, or by polymerization of amino acids) which comprise a primary structural conformation substantially duplicating part or all of that which is predicted to be extant at residues 266 through 287 of gD-1 and gD-2 [i.e., PELA(or V)PEDPEDSALLEDPV(or A)GTVA(or S)].Type: GrantFiled: January 31, 1985Date of Patent: May 17, 1988Assignee: University Patents, Inc.Inventors: Gary H. Cohen, Roselyn J. Eisenberg
-
Patent number: 4709011Abstract: Disclosed are immunologically active preparations of Herpes simplex virus envelope glycoproteins, gD-1 and gD-2. Preferably purified through use of a monoclonal anti-gD antibody immunodsorbent, gD-1 and gD-2 preparations are incorporated in vaccines useful in generating immunological responses protective against Herpes simplex virus disease states. Disclosed also is the preparation and use in vaccination procedures of synthetic polypeptides comprising amino acid squences which are: (1) substantially common to both gD-1 and gD-2; (2) cumulatively hydrophilic in nature; (3) specifically immunoreactive with a type common, monoclonal anti-gD antibody of Group VII classification. Vaccines incorporating the synthetic polypeptides give rise to protective immunological responses, e.g., they protect mice against Herpes simplex.Type: GrantFiled: May 15, 1985Date of Patent: November 24, 1987Assignee: University Patents, Inc.Inventors: Gary H. Cohen, Roselyn J. Eisenberg